Carbohydrate antigen 125 in atrial fibrillation

Atrial fibrillation is the most common arrhythmia in clinical settings. It is associated with an increased risk of death, stroke, and peripheral vascular embolism. Catheter ablation (CA) is an effective treatment for patients with AF. However, many studies have reported suboptimal outcomes, as AF recurrence rates often remain high after CA. Therefore, there is a need for early identification of patients who are prone to recurrence and require anti-inflammatory and/or antiarrhythmic treatment after CA. In recent years, Prediction of AF and AF recurrence after CA has become a hot topic in clinical practice. A lot of biomarkers (Such as B-type natriuretic peptide, N-terminal pro-BNP, high sensitivity C reactive protein etc.) have been identified as markers for predicting the risk of AF and AF recurrence after CA. Although these markers have been shown to predict AF and AF recurrence after CA, there are currently no relevant guidelines to indicate which of these markers have absolute predictive value. Therefore, Finding the appropriate indicators that can efficiently and accurately predict AF recurrence after AF ablation is important to provide the best treatment for each patient. These indicators still need exploration. Carbohydrate antigen 125 (CA-125) is a tumor marker suitable for the screening, diagnosis, and monitoring of ovarian malignant tumors. It has been widely studied in patients with heart failure. In recent years, the role of CA-125 in AF has been widely studied, and we provide a review in this article. It is wide availability and low cost provide additional advantages for its rapid implementation. This article reviews the role of CA-125 in patients with atrial fibrillation.